Literature DB >> 6450223

Long-term study of vascularized free-draining intraperitoneal pancreatic segmental allografts in beagle dogs.

G K Kyriakides, A Rabinovitch, D Mintz, L Olson, F T Rapaport, J Miller.   

Abstract

The purpose of the present study was to evaluate the significance of immunogenetic factors on the survival of pancreatic allografts in beagle dogs. Donors and recipients were leukocyte antigen (DLA)-typed and mixed lymphocyte culture (MLC)-tested. Recipients were made diabetic by total pancreatectomy and immediately implanted intraperitoneally with a vascularized, free-draining (duct unligated) pancreatic segmental (FDPS) allograft. Two groups of dogs were studied. In group I consisting of donor-recipient littermates, recipients were immunosuppressed with prednisone and azathioprine (n = 16 dogs), or not immunosuppressed (n = 4). In group II, recipients were made specifically unresponsive by total body radiation, autologous marrow implantation, and kidney transplantation from DLA-MLC identical donors, 1 yr before FDPS transplantation from the corresponding original kidney donors. Survival of the FDPS grafts in group I was inversely related to pretransplant MLC reactivity, irrespective of DLA genotyped match between donor and recipient. Thus, immunosuppressed high MLC reactors (n = 8) rejected FDPS grafts between 7 and 14 d, whereas immunosuppressed low MLC reactors (n = 8) accepted grafts for 25 to 260+ days, and nonimmunosuppressed low MLC reactors (n = 4) accepted grafts for 9-55 d. Rejection (hyperglycemia) of FDPS grafts was sudden, permanent, and unpredictable despite weekly intravenous glucose tolerance tests with measurements of glucose disappearance rates and serum insulin responses. Nevertheless, serial in vitro cell-mediated lymphocytotoxicity (CML) assays revealed increases in CML before graft rejection in low MLC reactors, and decreases in both CML and MLC responses before graft rejection in high MLC reactors. FDPS graft survival was indefinite (>6 mo) in group II dogs, despite low-grade MLC reactivity (2:4 dogs) and CML responses (4:4 dogs). Biopsies of FDPS grafts at 6 mo in normoglycemic dogs showed disappearance of exocrine tissue and coalescence of islets in both groups I and II, but with less fibrosis in group I (immunosuppressed). These results indicate that (a) pancreatic islets in vascularized grafts (FDPS) may survive indefinitely in the presence of a good tissue match best predicted by MLC testing, (b) tissue specific histocompatibility factors appear to be common enough between kidney and pancreas to allow for long-term survival of both organs transplanted from the same donor, at least in appropriate recipients (group II), and (c) immunosuppression is associated with less fibrosis in FDPS allografts.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6450223      PMCID: PMC371599          DOI: 10.1172/JCI110026

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  Mixed leukocyte culture reactivity and the outcome of bone marrow transplantation in dogs.

Authors:  R Bachvaroff; F D Cannon; D A Blumenstock; J W Ferrebee; F T Rapaport
Journal:  Transplant Proc       Date:  1978-03       Impact factor: 1.066

2.  THE INSULIN AND THE ZINC CONTENT OF NORMAL AND DIABETIC PANCREAS.

Authors:  D A Scott; A M Fisher
Journal:  J Clin Invest       Date:  1938-11       Impact factor: 14.808

3.  Intraperitoneal segmental pancreatic allografts with unligated ducts in pigs.

Authors:  G K Kyriakides; F Nuttall; J Miller
Journal:  Transplant Proc       Date:  1979-03       Impact factor: 1.066

4.  Pancreas allotransplantation without duodenum.

Authors:  W Meyer; P L Castelfranchi; O J Ruiz; C J Aquino; R C Lillehei
Journal:  J Surg Res       Date:  1972-02       Impact factor: 2.192

5.  Intraperitoneal transplantation of immediately vascularized segmental pancreatic grafts without duct ligation. A clinical trial.

Authors:  D E Sutherland; F C Goetz; J S Najarian
Journal:  Transplantation       Date:  1979-12       Impact factor: 4.939

6.  Functional characterization of blocking antibody after human renal transplantation.

Authors:  J Miller; J Lifton; F Rood; G Kyriakides; K Y Gajl-Peczalska; E J Yunis; B G Hattler
Journal:  Surgery       Date:  1974-07       Impact factor: 3.982

7.  Changes in human mixed lymphocyte culture reactivity as an indicator of kidney rejection.

Authors:  B G Hattler; J Miller
Journal:  Transplant Proc       Date:  1972-12       Impact factor: 1.066

8.  In vitro generation of human mixed lymphocyte culture suppressor cells. I. Cellular characterization and specificity.

Authors:  L Fuller; G Kyriakides; C Flaa; V Esquenazi; J Miller
Journal:  Transplantation       Date:  1980       Impact factor: 4.939

9.  A new method of preparation of segmental pancreatic grafts for transplantation: trials in dogs and in man.

Authors:  J M Dubernard; J Traeger; P Neyra; J L Touraine; D Tranchant; N Blanc-Brunat
Journal:  Surgery       Date:  1978-11       Impact factor: 3.982

10.  Induction of unresponsiveness to major transplantable organs in adult mammals: a recapitulation of ontogeny by irradiation and bone marrow replacement.

Authors:  F T Rapaport; R J Bachvaroff; N Mollen; H Hirasawa; T Asano; J W Ferrebee
Journal:  Ann Surg       Date:  1979-10       Impact factor: 12.969

View more
  3 in total

Review 1.  Pancreas and islet transplantation. I. Experimental studies.

Authors:  D E Sutherland
Journal:  Diabetologia       Date:  1981-03       Impact factor: 10.122

2.  Experimental vascularized segmental pancreatic and islet transplantation in the baboon.

Authors:  D F du Toit; J J Heydenrych; B Smit; G Louw; T Zuurmond; L Laker; D Els; A Weideman; S Wolfe-Coote; E A van der Merwe
Journal:  World J Surg       Date:  1984-04       Impact factor: 3.352

3.  Evaluation of insulin secretion after pancreas autotransplantation by oral or intravenous glucose challenge.

Authors:  P Calhoun; K S Brown; D A Krusch; E Barido; A H Farris; W G Schenk; L E Rudolf; D K Andersen; J B Hanks
Journal:  Ann Surg       Date:  1986-11       Impact factor: 12.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.